BTIG analyst Thomas Shrader maintained a Buy rating on Denali Therapeutics today and set a price target of $39.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Thomas Shrader has given his Buy rating due to a combination of factors tied to Denali’s differentiated science and commercial potential. He emphasizes that Denali’s direct PGRN replacement strategy, which uses a targeted delivery mechanism validated by the success of DNL310, appears fundamentally distinct from other failed approaches and therefore retains meaningful upside despite some biology risk highlighted by recent external setbacks.
Shrader also points to the strong profile of AVLAYAH, which demonstrates clear superiority over standard care through normalization of key disease biomarkers, implying broad uptake in new patients and durable, high-value treatment over time. Reflecting this larger market opportunity and full economics on the FTD-GRN program, he raises the price target to $39, even after trimming probability of success and increasing Denali’s assumed development and commercial costs, indicating a still-attractive risk‑reward profile for the stock.
In another report released on March 29, Stifel Nicolaus also maintained a Buy rating on the stock with a $41.00 price target.